Peroxisome proliferator-activated receptor γ and lung cancer biology

Journal of Investigative Medicine

Volumn 56, Issue 2, 2008, Pages 528-533

  Roman, Jesse ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Carcinogenesis; PPAR; Proliferation; Signaling; Tumor

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

APOPTOSIS; CANCER CELL; CANCER RESEARCH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; LUNG ALVEOLUS CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; REVIEW; TRANSCRIPTION INITIATION; TUMOR GROWTH; ANIMAL; CELL DIVISION; DRUG SCREENING; LUNG TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALIA;

ANIMALS; CELL DIVISION; HUMANS; LUNG NEOPLASMS; PPAR GAMMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85047685824     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181659932     Document Type: Review

References (57)

1. Michalik L, Desvergne B, Wahli W. Peroxisomeproliferator-activated receptors and cancers: complex stories. Nat Rev. 2004;4:61-70. (Pubitemid 38082154)
2. Han S, Roman J. Peroxisome proliferators-activated receptor gamma: a novel target for cancer therapeutics? Anticancer Drugs. 2007;18:237-244
3. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
4. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645-650.
5. Lock EA, Mitchell AM, Elcombe CR. Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annu Rev Pharmacol Toxicol. 1989;29:145-163.
6. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver x receptorYalpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 1997;46: 1319-1327.
7. Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137:354-366.
8. Diep QN, Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension. 2000;36:851-855.
9. Inoue I, Shino K, Noji S, et al. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun. 1998;246:370-374.
10. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573-25580.
11. Yan Q, Ito S, Gonzalez FJ. Hepatocyte-restricted constitutive activation of PPARα induces hepatoproliferation but not hepatocarcinogenesis. Carcinogenesis. 2007;28: 1171-1177.
12. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-435.
13. Sznaidman ML, Haffner CD, Maloney PR, et al. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPAR-delta)Vsynthesis and biological activity. Bioorg Med Chem Lett. 2003;13: 1517-1521.
14. Epple R, Azimioara M, Russo R, et al. 1,3,5-trisubstituted aryls as highly selective PPARdelta agonists. Bioorg Med Chem Lett. 2006;16:2969-2973.
15. Han S, Ritzenthaler JD, Wingerd B, et al. Activation of peroxisome proliferator-activated receptor beta/delta (PPARβδ) increases the expression of prostaglandin E2 receptor subtype E4. The role of phosphatidylinositol 3-kinase and CCAAAT/enhancer-binding protein beta. J Biol Chem. 2005;280:33240-33249.
16. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPAR gamma gene. J Biol Chem. 1997;272:18779-18789.
17. Fajas L, Fruchart JC, Auwerx J. PPAR-gamma3 mRNA: a distinct PPAR-gamma mRNA subtype transcribed from an independent promoter. FEBS Lett. 1998;438:55-60.
18. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
19. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipidactivated transcription factor. Cell. 1994;79:1147-1156.
20. Lehrke M, Lazar MA. The many faces of PPAR gamma. Cell. 2005;123:993-999.
21. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest. 2006;116:581-589.
22. Standiford TJ, Keshamouni VG, Reddy RC. Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc Am Thorac Soc. 2005; 2:226-231.
23. Istner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in bnx mice. Proc Natl Acad Sci U S A. 1998;95:8806-8811.
24. Lambe KG, Tugwood JD. A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem. 1996;239:1-7.
25. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998;1:465-470.
26. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med. 1998;4:1046-1052.
27. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol. 2002; 2:748-759.
28. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
29. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
30. Inoue K, Kawahito Y, Tsubouchi Y, et al. Expression of peroxisome proliferator-activated receptor (PPAR)- gamma in human lung cancer. Anticancer Res. 2001;21: 2471-2476.
31. Kerhamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator activated receptor gamma activation inhibits tumor progression in non small cell lung cancer. Oncogene. 2004;23:100-108.
32. Satoh T, Toyoda M, Hoshino H, et al. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene. 2002;21:2171-2180.
33. Li M, Lee TW, Yim AP, et al. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small cell lung cancer cells. J Cell Physiol. 2006;209:428-438.
34. Li M, Lee TW, Mok TS, et al. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem. 2005;96:760-774.
35. Zou W, Liu X, Yue P, et al. PPARg ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther. 2007;6:99-106.
36. Han S, Sidell N, Fisher PB, et al. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res. 2004;10:1911-1919.
37. Fulzele SV, Chatterjee A, Shaik MS, et al. 15-deoxy-detal 12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non small cell lines and xenograft tumors. Anticancer Drugs. 2007;18:65-78.
38. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPAR gamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther. 2006;5:430-437.
39. Han S, Zheng Y, Roman J. Rosiglitazone, an agonist of PPARg, inhibits non-small cell lung carcinoma cell proliferation in part through activation of tumor sclerosis complex-2. PPAR Res. 2007;2007:29632.
40. Sy L, Hur GY, Jung KH, et al. PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer. 2006;51:297-301.
41. Han S, Roman J. Suppression of prostaglandin E2 receptor subtype EP2 by PPAR-gamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun. 2004;31:1093-1099.
42. Limper AH, Roman J. Fibronectin: a versatile matrix protein with roles in thoracic development, repair and infection. Chest. 1992;101:1663-1673.
43. Han S, Sidell N, Roser-Page S, et al. Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase- 2 (COX-2) expression. Int J Cancer. 2004;111: 322-331.
44. Roman J, Ritzenthaler JD, Gil-Acosta A, et al. Nicotine and fibronectin expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling. FASEB J. 2004; 18:1436-1438.
45. Han S, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 2006;66:315-323.
46. Han S, Ritzenthaler JD, Sitaraman SV, et al. Fibronectin increases matrix metalloproteinase-9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells. J Biol Chem. 2006;281:29614-29624.
47. Han SW, Roman J. Extracellular matrix and aberrant signaling in lung carcinoma: role of fibronectin in control of lung carcinoma cell proliferation, apoptosis and resistance to therapy. Curr Sig Trans Ther. 2007;2:1-10.
48. Han S, Ritzenthaler JD, Rivera HN, et al. Peroxisome proliferator- activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1. Am J Physiol Lung Cell Mol Physiol. 2005;289:L419-L428.
49. Han S, Rivera HN, Roman J. Peroxisome proliferator-activated receptor-gamma ligands inhibit alpha5 integrin gene transcription in non-small cell lung carcinoma cells. Am J Respir Cell Mol Biol. 2005;32:350Y359.
50. Keshamouni VG, Arenberg DA, Reddy RC, et al. PPARgamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in nonYsmall cell lung cancer. Neoplasia. 2005;7:294-301.
51. Panigrahy D, Singer S, Shen LQ, et al. PPAR gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110:923-932.
52. Panigrahy D, Huang S, Kieran MW, et al. PPAR gamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther. 2005;4:687-693.
53. Ghosh AK, Bhattacharyya S, Lakos G, et al. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum. 2004;50:1305-1318.
54. Burgess HA, Daugherty LE, Thatcher TH, et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2005;288:L1146-L1153.
55. Van Ginderachter JA, Meerschaut S, Liu Y, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood. 2006;15: 525-535.
56. Theocharis S, Kanelli H, Politi E, et al. Expression of peroxisome proliferator-activated receptor-gamma in nonsmall cell lung carcinoma: correlation with histological type and grade. Lung Cancer. 2002;36:249-255.
57. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007;25: 1476-1481.